BACKGROUND: The incidence of neuroendocrine tumours (NET) has increased over the past three decades. Hepatic metastases which occur in up to 75% of NET patients significantly worsen their prognosis. New imaging techniques with increasing sensitivity enabling tumour detection at an early stage have been developed. The treatment encompasses a panel of surgical and non-surgical modalities. METHODS: This article reviews the published literature related to management of hepatic neuroendocrine metastases. RESULTS: Abdominal computer tomography, magnetic resonance tomography and somatostatin receptor scintigraphy are widely accepted imaging modalities. Hepatic resection is the only potentially curative treatment. Liver transplantation is justified in highly selected patients. Liver-directed interventional techniques and locally ablative measures offer effective palliation. Promising novel therapeutic options offering targeted approaches are under evaluation. CONCLUSIONS: The treatment of neuroendocrine liver metastases still needs to be standardized. Management in centres of expertise should be strongly encouraged in order to enable a multidisciplinary approach and personalized treatment. Development of molecular prognostic factors to select treatment according to patient risk should be attempted.
BACKGROUND: The incidence of neuroendocrine tumours (NET) has increased over the past three decades. Hepatic metastases which occur in up to 75% of NET patients significantly worsen their prognosis. New imaging techniques with increasing sensitivity enabling tumour detection at an early stage have been developed. The treatment encompasses a panel of surgical and non-surgical modalities. METHODS: This article reviews the published literature related to management of hepatic neuroendocrine metastases. RESULTS: Abdominal computer tomography, magnetic resonance tomography and somatostatin receptor scintigraphy are widely accepted imaging modalities. Hepatic resection is the only potentially curative treatment. Liver transplantation is justified in highly selected patients. Liver-directed interventional techniques and locally ablative measures offer effective palliation. Promising novel therapeutic options offering targeted approaches are under evaluation. CONCLUSIONS: The treatment of neuroendocrine liver metastases still needs to be standardized. Management in centres of expertise should be strongly encouraged in order to enable a multidisciplinary approach and personalized treatment. Development of molecular prognostic factors to select treatment according to patient risk should be attempted.
Authors: U Plöckinger; G Rindi; R Arnold; B Eriksson; E P Krenning; W W de Herder; A Goede; M Caplin; K Oberg; J C Reubi; O Nilsson; G Delle Fave; P Ruszniewski; H Ahlman; B Wiedenmann Journal: Neuroendocrinology Date: 2005-04-18 Impact factor: 4.914
Authors: Wojciech C Blonski; K Rajender Reddy; Abraham Shaked; Evan Siegelman; David C Metz Journal: World J Gastroenterol Date: 2005-12-28 Impact factor: 5.742
Authors: Jens Rosenau; Matthias J Bahr; Reinhard von Wasielewski; Michael Mengel; Hartmut H J Schmidt; Björn Nashan; Hauke Lang; Jürgen Klempnauer; Michael P Manns; Klaus H W Boeker Journal: Transplantation Date: 2002-02-15 Impact factor: 4.939
Authors: Christine S Landry; Guy Brock; Charles R Scoggins; Kelly M McMasters; Robert C G Martin Journal: Ann Surg Oncol Date: 2008-10-24 Impact factor: 5.344
Authors: Frederike G I van Vilsteren; Edwina S Baskin-Bey; David M Nagorney; Schuyler O Sanderson; Walter K Kremers; Charles B Rosen; Gregory J Gores; Timothy J Hobday Journal: Liver Transpl Date: 2006-03 Impact factor: 5.799
Authors: B Aussilhou; M Lesurtel; A Sauvanet; O Farges; S Dokmak; N Goasguen; A Sibert; V Vilgrain; J Belghiti Journal: J Gastrointest Surg Date: 2007-11-30 Impact factor: 3.452
Authors: Michael J Steward; Victoria S Warbey; Anmol Malhotra; Martyn E Caplin; John R Buscombe; Dominic Yu Journal: Radiographics Date: 2008 Jul-Aug Impact factor: 5.333
Authors: Linda S Sher; David M Levi; Julie S Wecsler; Mary Lo; Lydia M Petrovic; Susan Groshen; Lingyun Ji; Teresa Diago Uso; A Joseph Tector; Ann S Hamilton; J Wallis Marsh; Myron E Schwartz Journal: J Surg Oncol Date: 2015-07-14 Impact factor: 3.454
Authors: Jussara Hagen; Viviane P Muniz; Kelly C Falls; Sara M Reed; Agshin F Taghiyev; Frederick W Quelle; Francoise A Gourronc; Aloysius J Klingelhutz; Heather J Major; Ryan W Askeland; Scott K Sherman; Thomas M O'Dorisio; Andrew M Bellizzi; James R Howe; Benjamin W Darbro; Dawn E Quelle Journal: Cancer Res Date: 2014-10-01 Impact factor: 12.701
Authors: Manuel Weber; Lukas Kessler; Benedikt Schaarschmidt; Wolfgang Peter Fendler; Harald Lahner; Gerald Antoch; Lale Umutlu; Ken Herrmann; Christoph Rischpler Journal: BMC Cancer Date: 2020-04-16 Impact factor: 4.430